This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Nasdaq's Excels in Weekly Performance: 5 Best Stocks in ETF
by Sweta Killa
In a tug of war between bulls and bears, the Dow Jones and S&P 500 gained at least 1% each last week while the Nasdaq Composite Index advanced over 3%.
REGN vs. BMRN: Which Stock Is the Better Value Option?
by Zacks Equity Research
REGN vs. BMRN: Which Stock Is the Better Value Option?
REGN vs. BMRN: Which Stock Is the Better Value Option?
by Zacks Equity Research
REGN vs. BMRN: Which Stock Is the Better Value Option?
Why Is BioMarin (BMRN) Up 14.8% Since Last Earnings Report?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioMarin (BMRN) Beats on Q1 Earnings, Lowers Sales View
by Zacks Equity Research
BioMarin (BMRN) beats estimates for both earnings and sales in the first quarter. It lowers its total revenue outlook for the year due to the potential impact of coronavirus outbreak.
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings and Revenue Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 90.91% and 6.73%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
BioMarin (BMRN) Down 8% Since Last Earnings Report: Can It Rebound?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BioMarin (BMRN) Q4 Earnings Beat, Sales Miss, Valrox in Focus
by Zacks Equity Research
BioMarin (BMRN) announces mixed results for the fourth quarter of 2019, beating estimates for earnings while missing the same for sales.
Stock Market News for Feb 27, 2020
by Zacks Equity Research
U.S. equities disappointed on Wednesday, as most of the major benchmarks ended mostly lower.
BioMarin Pharmaceutical (BMRN) Q4 Earnings Top Estimates
by Zacks Equity Research
BioMarin (BMRN) delivered earnings and revenue surprises of 19.05% and -1.61%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?
BioMarin (BMRN) to Report Q4 Earnings: What's in the Cards?
by Zacks Equity Research
Key orphan disease drugs, Vimizim and Kuvan, are likely to have driven BioMarin's (BMRN) fourth-quarter top line.
BioMarin (BMRN) Catches Eye: Stock Jumps 6.1%
by Zacks Equity Research
BioMarin (BMRN) saw a big move last session, as its shares jumped more than 6% on the day, amid huge volumes.
BioMarin to Begin Early-Stage Study on Gene Therapy for PKU
by Zacks Equity Research
BioMarin (BMRN) is set to initiate dosing in an early-stage clinical study in the first quarter to evaluate its gene therapy candidate, BMN 307, in phenylketonuria, a rare disease affecting the brain.
BioMarin (BMRN) Catches Eye: Stock Jumps 5.8%
by Zacks Equity Research
BioMarin (BMRN) saw a big move last session, as its shares jumped nearly 6% on the day, amid huge volumes.
BioMarin (BMRN) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
BioMarin (BMRN) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
BioMarin Files BLA for Gene Therapy to Treat Hemophilia A
by Zacks Equity Research
BioMarin (BMRN) submits a BLA in the United States for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
by Zacks Equity Research
The Zacks Analyst Blog Highlights: uniQure, Sarepta Therapeutics, BioMarin Pharmaceutical and Sangamo Therapeutics
4 Solid Gene Therapy Buyout Bets Post Audentes-Astellas Deal
by Ekta Bagri
Gene therapy continues to draw attention with the recent spate of deals and acquisitions. We list four stocks with promising candidates in their pipelines that make attractive acquisition targets.
REGN or BMRN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
REGN vs. BMRN: Which Stock Is the Better Value Option?
The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion
by Zacks Equity Research
The Zacks Analyst Blog Highlights: Vertex, Biogen, BioMarin and Alexion
4 Big Drug Stocks Ripe for Takeover After NVS-MDCO Deal
by Kinjel Shah
Here are four stocks that boast promising prospects and are most likely to be takeout targets.
BioMarin Files MAA to EMA for Gene Therapy of Hemophilia A
by Zacks Equity Research
BioMarin (BMRN) submits an MAA in Europe for its investigational gene therapy valoctocogene roxaparvovec to treat adult patients with severe hemophilia A.
BioMarin (BMRN) Up 11% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
BioMarin (BMRN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
REGN or BMRN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
REGN vs. BMRN: Which Stock Is the Better Value Option?
Sarepta (SRPT) Q3 Loss Widens Y/Y, Revenues Beat Estimates
by Zacks Equity Research
Sarepta (SRPT) reports wider year-over-year loss. However, revenues increase year over year.